Review on Tauopathies: Clinicopathological Aspect

Abstract

A group of neurodegenerative diseases that differ in their morphology, biochemistry, and clinical presentation are Tauopathies. They are distinguished by aberrant tau protein accumulation in the brain. Currently, there is no conclusive method for preventing or curing tauopathies, but new scientific advancements have transformed this gloomy picture. Evidence from genetic research, experimental animal models, and molecular and cell biology has offered insight into the illnesses' underlying causes. Advances in radiology and biochemistry, notably in PET imaging, may offer critical biomarkers for clinical diagnosis and therapy. Tau, in addition to its role as a microtubule-associated tau protein, is involved in gene regulation, signal transduction, and metabolism. Experimental models allow for the development of novel diagnostic and treatment methods. Tauopathies are a set of disorders that can present with a wide range of clinical signs. It is still difficult to distinguish this disease from other protein-pathologies. In the last year, there has been a lot of interest in cerebrospinal fluid biomarkers and radiotracers. Although the accuracy of diagnosis in non-disease Alzheimer's tauopathies remains debatable, PET tau tracers may be utilised to identify disease process. Although primary tauopathies are uncommon and diverse conditions, their combined incidence, as well as the importance of tau malfunction in Alzheimer's disease and secondary tauopathies, make tauopathy research a top priority since it might assist many people.